Skip to main
EPRX

EPRX Stock Forecast & Price Target

EPRX Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eupraxia Pharmaceuticals is a promising investment opportunity due to its innovative drug delivery technology and current development programs targeting unmet medical needs. The company's EP-104GI product has demonstrated positive early clinical results and a potentially differentiated profile compared to existing treatments. While there are some risks to consider, including clinical development and commercial risks, the potential for long-term success and strong financials make Eupraxia Pharmaceuticals an attractive choice for investors.

Bears say

Eupraxia Pharmaceuticals is facing several challenges, including limited current market need for its EP-104 drug, uncertainty around its clinical success, and potential competition from cheaper off-label alternatives and existing treatments from larger companies. Additionally, the company's cross-border supply and tariffs may also pose a risk to its operations. Valuation is based on a probability-weighted DCF model, but risks such as financing and regulatory hurdles could hinder the company's success in the future.

EPRX has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eupraxia Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eupraxia Pharmaceuticals Inc (EPRX) Forecast

Analysts have given EPRX a Buy based on their latest research and market trends.

According to 4 analysts, EPRX has a Buy consensus rating as of Aug 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eupraxia Pharmaceuticals Inc (EPRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.